Withings discloses its newly Medical Advisory Board along with raising $60m Series B funding co-led by Gilde Healthcare, Idinvest Partners and Bpifrance

– FRANCE, Paris –  Withings, early pioneers of the connected health revolution, today announced a $60 million Series B funding round, co-led by healthcare investment specialists Gilde Healthcare, and long-term Withings partners and investors, Idinvest Partners and Bpifrance through their Large Venture funds as well as support from BNP Paribas Developpement, Oddo BHF Private Equity and Adelie Capital.

As Withings deepens its ongoing healthcare strategy, it will be guided by its newly appointed global Medical Advisory Board, comprised of eminent medical, research, and scientific leaders: Dr. John Halamka, President of the Mayo Clinic Platform, Dr. Stéphane Laurent, former Head of Clinical Pharmacology in Hôpital Européen Georges Pompidou in Paris, and Craig Lipset, former head of Clinical Innovation at Pfizer.

With this new investment and the medical support of the new advisory board, Withings aims to invent a new generation of consumer health devices that will track new biomarkers and bring medical-grade, predictive capabilities into the home.

Having led a paradigm shift in the way consumers and physicians interact by enabling accurate and regular patient-generated data collection, Withings will capitalize on this investment to solidify its position as a trusted intermediary between patients and healthcare professionals. It will continue to invest in products and data services that help deliver more personalized, continuous and preventive medicine.

The company will invest funds to globally scale its dedicated business-to-business division Withings MED PRO that serves health professionals and accelerate the development of the next generation of consumer health devices that bring medical grade and predictive capabilities into the home. It also plans to add 100 new positions in the United States and in France by the end of the year to strengthen its teams working on research and development, sales, and marketing.In 2008, a small group of engineers created Withings, launching the world’s first connected scale in 2009. The team quickly discovered being able to regularly access information gave users a new power: manage their weight and take control of their health daily.

Today, Withings has built the largest ecosystem of connected, non-invasive health devices by reinventing everyday objects and endowing them with new medical powers: a scale that measures arterial stiffness, an analog watch that detects cardiac arrhythmias, a blood pressure monitor that detects valvular heart diseases or an under-mattress sleep tracker that detects sleep apnea. With over 45 technical patents, the Withings portfolio captures more than 20 vital health parameters including blood pressure, ECG, weight, pulse wave velocity, heart rate, activity levels, sleep apnea, and sleep patterns.

With people spending most of their time outside of the doctor’s office, at-home health monitors not only give consumers more control over their health, they have extraordinary potential for doctors, hospitals and researchers. Having remote and regular access to precise medical-grade data allows professionals to offer more personalized, intelligent, and responsive care.

In 2019, Withings launched MED PRO, a dedicated business-to-business division that allows medical professionals, institutions, payers, disease management programs, coaching platforms, and researchers to leverage Withings devices and data analytics within their own ecosystems. With today’s funding and against the current health emergency backdrop, Withings is actively growing this division. It offers remote patient and telemedicine services and solutions for dedicated health programs that manage chronic diseases such as diabetes, hypertension, heart health, sleep, and weight management.

In addition, MED PRO aids academic and pharma research, having been involved in over 100 clinical and academic studies by leading organizations such as Mayo Clinic, Harvard University, the European Georges Pompidou Hospital, the American Medical Group Association, Scripps Health. This also includes a current research initiative with the Department of Cardiology at the University Hospital of the Ludwig-Maximilian’s University of Munich, Germany, which is integrating its soon to be launched ScanWatch into a Covid-19 patient monitoring project. The ScanWatch is capable of tracking the blood oxygen saturation and the heart rhythm by wrist measurements.

From a small group of engineers, the Withings team has grown in size and scope to include people with diverse and non-conventional electronics backgrounds such as cardiologists, psychologists, a sleep doctor, and even a philosopher.

Eric Carreel, President and co-founder of Withings: “I strongly believe in technology’s ability to transform society’s health by allowing anyone to regularly monitor their vitals from home and involve health professionals in this process. Today, we are in an exciting time where medicine is becoming personalized, continuous, and based on data analysis, and I am proud Withings is at the heart of this revolution. With funding from like-minded partners, we can scale our efforts globally and continue to invest in new technologies and AI tools that can detect and predict medical conditions.”

Mathieu Letombe, CEO of Withings: “This is an important milestone for Withings. We have combined technology and medical science during the past ten years to create an unrivaled portfolio of devices that continually and accurately measure a vast array of health parameters. With the healthcare industry increasingly embracing this technology and data, it has enthusiastically turned to Withings as a natural partner. Our devices enjoy some of the highest retention levels, cover more health vitals and work with more operating platforms than any other player in the business. The new influx of funding and medical expertise will help us bring even more exciting solutions to the market, making the possibilities for the next ten years boundless.”

Edwin de Graaf, Managing Partner at Gilde Healthcare commented: “With telemedicine on the rise, and the wider health industry’s growing need to collect and analyze accurate, reliable patient data, Withings is in a unique position to thrive and is an attractive investment for us. We look forward to working with the Withings team as they continue to redefine how patients and physicians interact.” Benoit Grossman, Managing Partner at Idinvest Partners: “Withings has demonstrated its leadership in creating elegantly designed connected health devices that millions of consumers want and continue to use. We’ve worked with the company since its infancy and are excited to be part of it as it enters this new era of opportunity.”

About Withings

Founded by visionary innovators Eric Carreel and Cédric Hutchings in 2008, the Withings team of engineers, doctors, and health professionals invent the world’s most efficient devices to help track and analyze anyone’s vitals. The ecosystem range includes award-winning products across the health spectrum, including hybrid smartwatches and health trackers, connected scales, blood pressure monitors, and an advanced sleep system. Every piece of collected data comes to life in the free Health Mate app, where users can find coaching, motivation, and valuable insights to share with their doctors and shape key aspects of their health.

For more information: https://www.withings.com

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion ($1.5 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast-growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market.

For more information: https://gildehealthcare.com

About Idinvest Partners

Idinvest Partners is a leading European mid-market private equity firm. With €9bn under management, the firm has developed several areas of expertise including innovative startup venture capital transactions; mid-market private debt, i.e. senior and subordinated debt; primary and secondary investment and private equity advisory services. Founded in 1997, Idinvest Partners used to belong to the Allianz Group until 2010, when it branched out as an independent firm. In January 2018, Idinvest Partners became a subsidiary of Eurazeo, a leading global investment company, with a diversified portfolio of €18.8bn in assets under management, including nearly €12.5bn from investment partners, invested in nearly 430 companies.

About Bpifrance

Bpifrance is the French national investment bank: it finances businesses—at every stage of their development—through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy.) to help entrepreneurs meet their challenges (innovation, export…).

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.